Bacterial infections of skin and wounds may seriously decrease the quality of life and even
cause death in some patients. One of the largest concerns in their treatment is the growing …

The frequency of co-infections with bacterial or fungal pathogens has constantly increased
among critically ill patients with coronavirus disease 2019 (COVID-19) during the pandemic …

Candida auris is an opportunistic fungal pathogen and an emerging global public health
threat, given its high mortality among infected individuals, antifungal resistance, and …

Candida auris is a multidrug resistant (MDR) fungal pathogen with a crude mortality rate of
30-60%. First identified in 2009, C. auris has been rapidly emerging to become a global risk …

Background New and emerging infectious diseases continue to represent a public health
threat. Emerging infectious disease threats include pathogens increasing in range (eg …

Background Candida auris infections have been reported worldwide since the pathogen
was isolated in 2009. Aim To analyse the incidence of cutaneous and intestinal colonization …

Invasive fungal infections are increasingly encountered with the expansion of iatrogenic
immunosuppression, including not only solid organ and hematopoietic stem cell transplant …

Candida auris is a multidrug‐resistant pathogen yeast that produces nosocomial outbreaks,
due to its ability in colonizing the skin, mucous membranes and surfaces. Rapid diagnosis is …

Background Candida auris was first described in Japan in 2009 and has since been
detected in over 40 countries. The yeast is concerning for multiple reasons, primarily:(1) …

Objectives: Identify the etiology of Candida auris infection. Review the appropriate
evaluation of Candida auris. Outline the management options available for Candida auris …